Figure 3.

MDM2 mitigates apoptosis in central memory T cells and enhances metabolic fitness and polyfunctionality. Naïve human CD8+ T cells were activated with CD3/CD28/IL-2 for 5 days at different concentration of Navtemadlin as indicated. (A) Number of total live cells and viability and (B) number of live central and effector memory (right) were shown (n ≥ 3 biological replicates). (C) Representative Annexin V and PI flow plots for central (top) and effector (bottom) memory at 0μM and 1μM of Navtemadlin on day 5. Frequency of live (Annexin V- PI-), early apoptotic (Annexin V+ PI-), late apoptotic (Annexin V+ PI+), and necrotic (Annexin V- PI+) were plotted as seen in the bar plots (n = 3 biological replicates). (D) Representative flow plots of granzyme B (GzB) and interferon-gamma (IFN-γ) at 0μM and 1μM of Navtemadlin after 5-day culture (left). Frequency of polyfunctional CD8+ T cells were quantified (right) (n ≥ 3 biological replicates). (E) Oxygen consumption rate (OCR) and spare respiratory capacity (SRC) at 0μM and 1 μM of Navtemadlin (n ≥ 3 biological replicates). Oligomycin was injected after the 3rd measurement (approximately at minute 12), FCCP after the 6th measurement (approximately at minute 25), and rotenone and antimycin A after the 10th measurement (approximately at minute 40). Asterisks indicate statistical significance by one-way ANOVA followed by Dunnett’s multiple comparisons test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Bars represent mean and error bars indicate SEM. Colored asterisk indicate significant difference compared to 0 μM NAV control.